Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study

Authors:
  • GAGalsky
    Galsky
  • MRM. Retz
    M. Retz
  • ASA.O. Siefker-Radtke
    A.O. Siefker-Radtke
  • ABA. Baron
    A. Baron
  • ANA. Necchi
    A. Necchi
  • JBJ. Bedke
    J. Bedke
  • EPE.R. Plimack
    E.R. Plimack
  • DVD. Vaena
    D. Vaena
  • MGM.-O. Grimm
    M.-O. Grimm
  • SBS. Bracarda
    S. Bracarda
  • JAJ. Arranz Arija
    J. Arranz Arija
  • SPS.K. Pal
    S.K. Pal

Abstract
Background: Chemotherapy for platinum-resistant advanced mUC yields poor objective response rates (ORR) and overall survival (OS). Nivolumab (NIVO) recently showed promising efficacy and safety in the CheckMate 032 phase I/II study (NCT01928394) in this setting. The current larger study, CheckMate 275 (NCT02387996), investigated efficacy and safety of NIVO in patients (pts) with mUC or surgically unresectable locally advanced UC that progressed after platinum-based chemotherapy.